Market Overview

Why Acasti Pharma's Stock Is Trading Higher Today

Why Acasti Pharma's Stock Is Trading Higher Today

Acasti Pharma (NASDAQ: ACST) shares are trading higher on Monday after B.Riley FBR upgraded the stock from Neutral to Buy and announced a price target of $2 per share.

Acasti Pharma is a biopharmaceutical innovator advancing a cardiovascular drug, CaPre (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. The company is focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the blood lipids associated with cardiovascular disease risk.

The company is developing CaPre in a Phase 3 clinical program in patients with severe hypertriglyceridemia

Acasti Pharma shares were trading up 16.74% at 62 cents on Monday. The stock has a 52-week high of $3.08 and a 52-week low of 25 cents.

Latest Ratings for ACST

Sep 2020Aegis CapitalDowngradesBuyHold
Sep 2020B. Riley FBRDowngradesBuyNeutral
Sep 2020OppenheimerDowngradesOutperformPerform

View More Analyst Ratings for ACST
View the Latest Analyst Ratings


Related Articles (ACST)

View Comments and Join the Discussion!

Posted-In: why it's movingPenny Stocks Upgrades Price Target Analyst Ratings

Latest Ratings

BIIBRBC CapitalMaintains277.0
RLICompass PointInitiates Coverage On90.0
CSCOWolfe ResearchDowngrades42.0
GILDRBC CapitalMaintains86.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at